Insuman Comb 15 Solostar (Insulin Human)

Insulin human mimics the natural hormone insulin. It binds to insulin receptors on muscle, fat and liver cells, activating a signaling cascade that moves glucose‑transport proteins to the cell surface, allowing glucose to enter cells for energy. It also suppresses liver production of glucose, lowering overall blood‑sugar levels.

The dose is individualized and set by a qualified prescriber. It is based on factors such as the patient’s current blood‑glucose readings, carbohydrate intake, body weight, renal function, and overall treatment goals. Patients should follow the dosing schedule and adjustments recommended by their healthcare professional.

Safety data are limited. Insulin is generally considered the preferred glucose‑lowering therapy in pregnancy because it does not cross the placenta in harmful amounts. Use during pregnancy or while breastfeeding should only occur when the prescriber judges that the benefits to the mother outweigh any potential risks to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Insuman Comb 15 Solostar contains human insulin in a fixed ratio of rapid‑acting and intermediate‑acting components, similar to other premixed products such as NovoMix 30 or Humalog Mix 25. Compared with analog‑based mixes, human‑insulin mixes may have a slightly different onset and duration, but they all aim to simplify basal‑bolus therapy with fewer daily injections.

The product must be stored refrigerated at 2 °C to 8 °C. Keep it in the original carton to protect from light, do not freeze, and avoid shaking the vial. Once in use, most premixed insulins remain stable for up to 28 days at room temperature, but check the label for the exact in‑use period.

It is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce lipodystrophy. Patients should use a sterile needle, follow aseptic technique, and inject the prescribed dose at the times indicated by their healthcare provider, usually before meals and at bedtime.

The most critical risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Omission of doses in insulin‑dependent patients may lead to diabetic ketoacidosis, a life‑threatening condition requiring immediate medical attention.

Patients with known hypersensitivity to human insulin or any excipients in the formulation should avoid it. It is also contraindicated in individuals experiencing acute hypoglycemia until glucose levels are corrected. Caution is advised for those with severe renal or hepatic impairment, and prescribers should evaluate each case individually.